Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Andrew Peter Dean"'
Autor:
Zev A. Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo-Cid, Sreenivasa R Chandana, Christelle De La Fouchardiere, Andrew Peter Dean, Igor Kiss, Woojin Lee, Thorsten Oliver Goetze, Eric Van Cutsem, Andrew Scott Paulson, Tanios S. Bekaii-Saab, Shubham Pant, Richard Hubner, Zhimin Xiao, Huanyu Chen, Fawzi Benzaghou, Eileen Mary O'Reilly
Publikováno v:
Journal of Clinical Oncology. 41:LBA661-LBA661
LBA661 Background: Liposomal irinotecan administered with 5-fluorouracil/leucovorin (5-FU/LV) is approved in the USA and Europe for mPDAC following progression with gemcitabine-based therapy. A phase 1/2 study (Wainberg et al. Eur J Cancer 2021;151:1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::adedb988a055c95df9b251d7f4a27304
https://doi.org/10.1200/jco.2023.41.4_suppl.lba661
https://doi.org/10.1200/jco.2023.41.4_suppl.lba661
Autor:
Alice Talbot, Andrew Peter Dean, Aine McClean, Michelle Colfer, Cormac Newell, Sarah Theze, Adarsh Das, Conor McCartney, Eoin Walsh, Niamh Crowley, Cliodhna Tutty-Bardon, Emma Shaughnessy
Publikováno v:
Journal of Clinical Oncology. 40:e16252-e16252
e16252 Background: Pancreatic cancer has one of the poorest prognoses of all solid tumours with median overall survival rate between 9 and 12 months worldwide. (1, 2) Treatment guidelines beyond first line chemotherapy are subsequently limited by a p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c844cad631af301e18a443409f9ad7a
https://doi.org/10.1200/jco.2022.40.16_suppl.e16252
https://doi.org/10.1200/jco.2022.40.16_suppl.e16252
Publikováno v:
Journal of Clinical Oncology. 40:e13648-e13648
e13648 Background: Malignancy associated thrombosis places a significant clinical and financial burden on all major oncology services worldwide. Cancer patients are at an increased risk of thrombosis and large studies have suggested a subsequent incr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::59b1f0c7cf008d133f3783001e1116d9
https://doi.org/10.1200/jco.2022.40.16_suppl.e13648
https://doi.org/10.1200/jco.2022.40.16_suppl.e13648
Publikováno v:
Journal of Clinical Oncology. 37:e17586-e17586
e17586 Background: Advanced anaplastic thyroid cancer is a disease with very few treatment options. Poor response rates have been reported with cisplatin / doxorubicin and modest response noted in a single phase 2 trial with 24 hour paclitaxel infusi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d0f2506a6a5ea6e8b9f2cdb1aaa1a5c
https://doi.org/10.1200/jco.2019.37.15_suppl.e17586
https://doi.org/10.1200/jco.2019.37.15_suppl.e17586